Now showing 1 - 10 of 14
  • 2016Book Chapter
    [["dc.bibliographiccitation.firstpage","153"],["dc.bibliographiccitation.lastpage","176"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Schmitz, Jessica"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.editor","Oellerich, Michael"],["dc.contributor.editor","Dasgupta, Amitava"],["dc.date.accessioned","2020-05-22T06:58:17Z"],["dc.date.available","2020-05-22T06:58:17Z"],["dc.date.issued","2016"],["dc.description.abstract","Genome transplant dynamics is a particularly promising new approach for the detection of graft injury based on the determination of graft-derived circulating cell-free DNA (cfDNA) in the blood of the recipient. An increase of donor DNA is an early indication of organ damage. A novel potential routine assay for graft-derived circulating cfDNA quantification has been developed using droplet digital polymerase chain reaction for the determination of the donor/recipient circulating cfDNA ratio. This method is very cost-effective and provides results on the same day. Monitoring graft-derived cfDNA has the advantage that it directly interrogates the health of the donor organ, and it allows early detection of transplant injury (“liquid biopsy”). The detection of subclinical rejection would be desirable to allow early intervention. Undiagnosed chronic damage can result in chronic rejection. The determination of graft-derived circulating cfDNA may complement or possibly replace other approaches for post-transplant monitoring, and it may improve the chances of long-term graft survival. This method will be helpful to individualize immunosuppressive regimens. Personalized immunosuppression will in the future shift emphasis from reaction to prevention, which could make immunosuppressive drugs safer and more effective and also reduce the cost of health care."],["dc.identifier.doi","10.1016/B978-0-12-800885-0.00007-2"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65676"],["dc.language.iso","en"],["dc.publisher","Elsevier"],["dc.publisher.place","San Diego"],["dc.relation.doi","10.1016/C2013-0-19247-1"],["dc.relation.isbn","978-0-12-800885-0"],["dc.relation.ispartof","Personalized Immunosuppression in Transplantation"],["dc.title","Graft-derived cell-free DNA as a marker of graft integrity after transplantation"],["dc.type","book_chapter"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]
    Details DOI
  • 2014Conference Abstract
    [["dc.bibliographiccitation.journal","American Journal of Transplantation"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Oellerich, M."],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Beck, J."],["dc.contributor.author","Schmitz, J."],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","SchĂĽtz, Ekkehard"],["dc.date.accessioned","2018-11-07T09:39:13Z"],["dc.date.available","2018-11-07T09:39:13Z"],["dc.date.issued","2014"],["dc.format.extent","874"],["dc.identifier.isi","000338033304007"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33231"],["dc.notes.status","zu prĂĽfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","World Transplant Congress"],["dc.relation.eventlocation","San Francisco, CA"],["dc.relation.issn","1600-6143"],["dc.relation.issn","1600-6135"],["dc.title","Graft-Derived Cell-Free DNA (GcfDNA) as a Sensitive Measure of Individual Graft Integrity After Liver Transplantation."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]
    Details WOS
  • 2017Book Chapter
    [["dc.bibliographiccitation.firstpage","373"],["dc.bibliographiccitation.lastpage","386"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Blum, Anna"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.editor","Preedy, V. R."],["dc.contributor.editor","Patel, V. B."],["dc.date.accessioned","2020-05-22T07:14:29Z"],["dc.date.available","2020-05-22T07:14:29Z"],["dc.date.issued","2017"],["dc.description.abstract","Improvement of long-term patient and graft outcome is still a challenge in liver transplantation. Personalized approaches to immunosuppressive treatment of liver transplant patients are currently under investigation, as conventional markers have limited usefulness to predict drug efficacy. The presence of graft-derived cell-free DNA (GcfDNA) in the plasma of liver transplant recipients opens up the possibility of monitoring allograft injury through measurement of this molecular marker. A rapid, cost-effective droplet digital PCR (ddPCR) method has been developed for the quantification of donor DNA. GcfDNA has shown to be useful for the detection of subclinical and full-blown acute rejection and non-rejection-related liver injury (e.g., HCV infection, liver trauma, ischemia/reperfusion damage). GcfDNA allows for the early detection of transplant injury (“liquid biopsy”) and enables earlier more effective treatment intervention. It is especially helpful to guide changes in immunosuppression and to monitor immunosuppression minimization. This new approach may contribute to achieve more effective, less toxic personalized immunosuppression."],["dc.identifier.doi","10.1007/978-94-007-7675-3_10"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65684"],["dc.language.iso","en"],["dc.publisher","Springer"],["dc.publisher.place","Dordrecht"],["dc.relation.eisbn","978-94-007-7675-3"],["dc.relation.isbn","978-94-007-7674-6"],["dc.relation.ispartof","Biomarkers in Liver Disease"],["dc.title","Graft-derived cell-free DNA as a biomarker in liver transplantation"],["dc.type","book_chapter"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]
    Details DOI
  • 2014Conference Abstract
    [["dc.bibliographiccitation.firstpage","713"],["dc.bibliographiccitation.journal","American Journal of Transplantation"],["dc.bibliographiccitation.lastpage","714"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Oellerich, M."],["dc.contributor.author","SchĂĽtz, Ekkehard"],["dc.contributor.author","Schmitz, J."],["dc.contributor.author","Beck, J."],["dc.contributor.author","Slotta, Jan Erik"],["dc.contributor.author","Walson, Philip D."],["dc.date.accessioned","2018-11-07T09:39:13Z"],["dc.date.available","2018-11-07T09:39:13Z"],["dc.date.issued","2014"],["dc.identifier.isi","000338033303192"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33230"],["dc.notes.status","zu prĂĽfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","World Transplant Congress"],["dc.relation.eventlocation","San Francisco, CA"],["dc.relation.issn","1600-6143"],["dc.relation.issn","1600-6135"],["dc.title","Potential of Graft-Derived Cell-Free DNA Quantification to Improve Outcomes With Marginal Donor Organs - Case Report of Successful Liver Transplantation of a HELLP Syndrome Donor."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]
    Details WOS
  • 2014Conference Abstract
    [["dc.bibliographiccitation.journal","Transplantation Journal"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Oellerich, M."],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Beck, J."],["dc.contributor.author","Schmitz, J."],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","SchĂĽtz, Ekkehard"],["dc.date.accessioned","2018-11-07T09:37:41Z"],["dc.date.available","2018-11-07T09:37:41Z"],["dc.date.issued","2014"],["dc.format.extent","874"],["dc.identifier.isi","000339104605413"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32898"],["dc.notes.status","zu prĂĽfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.publisher.place","Philadelphia"],["dc.relation.conference","World Transplant Congress"],["dc.relation.eventlocation","San Francisco, CA"],["dc.relation.issn","1534-6080"],["dc.relation.issn","0041-1337"],["dc.title","Graft-Derived Cell-Free DNA (GcfDNA) as a Sensitive Measure of Individual Graft Integrity After Liver Transplantation."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]
    Details WOS
  • 2014Conference Abstract
    [["dc.bibliographiccitation.firstpage","S241"],["dc.bibliographiccitation.journal","Liver Transplantation"],["dc.bibliographiccitation.lastpage","S242"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Slotta, Jan Erik"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Schuetz, Ekkehardt"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Kollmar, Otto"],["dc.date.accessioned","2018-11-07T09:39:07Z"],["dc.date.available","2018-11-07T09:39:07Z"],["dc.date.issued","2014"],["dc.identifier.isi","000339959602142"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33206"],["dc.notes.status","zu prĂĽfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","Joint International Congress of ILTS, ELITA and LICAGE"],["dc.relation.eventlocation","London, ENGLAND"],["dc.relation.issn","1527-6473"],["dc.relation.issn","1527-6465"],["dc.title","Graft Derived Cell-Free DNA as an Early Organ Integrity Biomarker after Liver Transplantation of a HELLP Syndrome Donor Liver."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]
    Details WOS
  • 2016Review
    [["dc.bibliographiccitation.firstpage","S75"],["dc.bibliographiccitation.journal","Therapeutic Drug Monitoring"],["dc.bibliographiccitation.lastpage","S79"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Schmitz, Jessica"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","SchĂĽtz, Ekkehard"],["dc.date.accessioned","2020-12-10T18:19:52Z"],["dc.date.available","2020-12-10T18:19:52Z"],["dc.date.issued","2016"],["dc.description.abstract","Although short-term success after solid organ transplantation is good, long-term graft and recipient survival are both not satisfactory. Despite therapeutic drug monitoring (TDM) of immunosuppressive drugs (ISDs), both excessive and insufficient immunosuppression still do occur. There is a need for new biomarkers that, when combined with TDM, can be used to provide more effective and less toxic, personalized immunosuppression to improve long-term survival. Currently used methods are insufficient to rapidly, cost-effectively, and directly interrogate graft integrity after solid organ transplantation. However, because organ transplants are also genome transplants, measurement of graft-derived circulating cell-free DNA (GcfDNA) has shown promise as a way to improve both graft and recipient outcomes after solid organ transplantation through the early detection of severe graft injury, enabling an early intervention. A newly developed droplet digital polymerase chain reaction (ddPCR) method has advantages over expensive high-throughput sequencing methods to rapidly quantify GcfDNA percentages and absolute amounts. This procedure does not require donor DNA and therefore can be applied to any organ donor/recipient pair. The droplet digital polymerase chain reaction method allows for the early, sensitive, specific, and cost-effective direct assessment of graft integrity and can be used to define individual responses to ISDs including the minimal ISD exposures necessary to prevent rejection. This is especially important in patients undergoing ISD switches due to ISD toxicity, infections, or malignancies. Although prospective, multicenter clinical trials in liver, heart, and kidney transplantation have not been completed, early results suggest that GcfDNA can be combined with TDM to guide changes in immunosuppression to provide more effective, and less toxic treatment. Personalized immunosuppression will shift emphasis in transplantation from reaction to prevention and could improve outcome at lower health care costs."],["dc.identifier.doi","10.1097/FTD.0000000000000239"],["dc.identifier.isi","000377003400009"],["dc.identifier.issn","0163-4356"],["dc.identifier.pmid","26418703"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75409"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.status","zu prĂĽfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1536-3694"],["dc.relation.issn","0163-4356"],["dc.title","Graft-Derived Cell-Free DNA as a Marker of Transplant Graft Injury"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC WOS
  • 2013Journal Article
    [["dc.bibliographiccitation.firstpage","1732"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Clinical Chemistry"],["dc.bibliographiccitation.lastpage","1741"],["dc.bibliographiccitation.volume","59"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Bierau, Sarah"],["dc.contributor.author","Balzer, Stefan"],["dc.contributor.author","Andag, Reiner"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Schmitz, Jessica"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Mörer, Onnen"],["dc.contributor.author","Slotta, Jan E."],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Schütz, Ekkehard"],["dc.date.accessioned","2020-05-22T07:07:40Z"],["dc.date.available","2020-05-22T07:07:40Z"],["dc.date.issued","2013"],["dc.description.abstract","BACKGROUND Cell-free DNA (cfDNA) from grafts in the circulation of transplant recipients is a potential biomarker of rejection. Its usefulness was investigated after heart transplantation during the maintenance phase by use of microarrays and massive parallel sequencing of donor and recipient DNA. Disadvantages of these methods are high costs, long turnaround times, and need for donor DNA. Therefore, we sought to develop a rapid and cost-effective method using digital droplet PCR (ddPCR). METHODS Plasma samples were collected from stable recipients after liver (LTx, n = 10), kidney (KTx, n = 9), and heart (HTx, n = 8) transplantation as well as from 7 additional patients directly after LTx. Known single-nucleotide polymorphisms were selected for high minor allelic frequencies, of which 41 hydrolysis probe assays were established. Plasma cfDNA was preamplified, followed by conventional real-time PCR to define informative (heterologous) SNPs, which were then used for quantification (percentage) of graft-derived cfDNA (GcfDNA) using ddPCR. RESULTS Mean recovery was 94% (SD, 13%) with an imprecision of 4%–14% with the use of controls with 2% minor allele. GcfDNA in stable patients was <6.8% (LTx), <2.5% (KTx), and <3.4% (HTx). On the day of LTx, GcfDNA was approximately 90% and by day 10 it was <15% in complication-free LTx recipients. In 2 patients with biopsy-proven rejection, GcfDNA increased to >60%, whereas in 1 patient with cholestasis no increase was found. CONCLUSIONS A novel, cost-effective, rapid technique was developed to quantify GcfDNA in transplant recipients. This technique embodies a promising, potentially universal biomarker for early detection of rejection, which could enable more effective therapeutic interventions."],["dc.identifier.doi","10.1373/clinchem.2013.210328"],["dc.identifier.pmid","24061615"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65680"],["dc.language.iso","en"],["dc.relation.eissn","1530-8561"],["dc.relation.issn","0009-9147"],["dc.title","Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]
    Details DOI PMID PMC
  • 2014Conference Abstract
    [["dc.bibliographiccitation.journal","Transplant International"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","Beck, J."],["dc.contributor.author","Schmitz, J."],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Slotta, Jan Erik"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Oellerich, M."],["dc.contributor.author","SchĂĽtz, Ekkehard"],["dc.date.accessioned","2018-11-07T09:34:43Z"],["dc.date.available","2018-11-07T09:34:43Z"],["dc.date.issued","2014"],["dc.format.extent","50"],["dc.identifier.isi","000342752400154"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32234"],["dc.notes.status","zu prĂĽfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.issn","1432-2277"],["dc.relation.issn","0934-0874"],["dc.title","USE OF PLASMA GCFDNA QUANTIFICATION TO GUIDE PERSONALIZED IMMUNOSUPPRESSION"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]
    Details WOS
  • 2014Conference Abstract
    [["dc.bibliographiccitation.firstpage","S107"],["dc.bibliographiccitation.journal","Liver Transplantation"],["dc.bibliographiccitation.lastpage","S108"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Slotta, Jan Erik"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Birau, Sarah"],["dc.contributor.author","Balzer, Stefan"],["dc.contributor.author","Andag, Reiner"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Schmitz, Jessica"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Moerer, Onnen"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Schuetz, Eckehardt"],["dc.contributor.author","Kollmar, Otto"],["dc.date.accessioned","2018-11-07T09:39:07Z"],["dc.date.available","2018-11-07T09:39:07Z"],["dc.date.issued","2014"],["dc.identifier.isi","000339959601015"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33207"],["dc.notes.status","zu prĂĽfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","Joint International Congress of ILTS, ELITA and LICAGE"],["dc.relation.eventlocation","London, ENGLAND"],["dc.relation.issn","1527-6473"],["dc.relation.issn","1527-6465"],["dc.title","Quantification of Donor DNA in the Circulation after Liver Transplantation As a Potential Universal Rejection Biomarker Using Digital Droplet PCR."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]
    Details WOS